5 year follow-up from the PROVIDE trial suggests that additional parenteral AA (1 g/d for 5 days) in ELBW infants does not improve school-age neurocognitive outcomes, and may have potential adverse effects on muscle strength and psychosocial function: buff.ly/cwQ0idh
#EBNEOalerts #neoEBM #neosky
